Small molecule screening in zebrafish: swimming in potential drug therapies
- Authors
- Tamplin, O.J., White, R.M., Jing, L., Kaufman, C.K., Lacadie, S.A., Li, P., Taylor, A.M., and Zon, L.I.
- ID
- ZDB-PUB-130710-75
- Date
- 2012
- Source
- Wiley Interdisciplinary Reviews: Developmental Biology 1(3): 459-468 (Review)
- Registered Authors
- Jing, Lili, Tamplin, Owen, Taylor, Alison, White, Richard M., Zon, Leonard I.
- Keywords
- none
- MeSH Terms
-
- Animals
- Embryo, Nonmammalian/drug effects*
- Embryo, Nonmammalian/metabolism*
- Genetic Testing*
- Phenotype
- Small Molecule Libraries/pharmacology*
- Zebrafish/embryology
- Zebrafish/genetics*
- PubMed
- 23801494 Full text @ Wiley Interdiscip. Rev. Dev. Biol.
Phenotype-driven chemical genetic screens in zebrafish have become a proven approach for both dissection of developmental mechanisms and discovery of potential therapeutics. A library of small molecules can be arrayed into multiwell plates containing zebrafish embryos. The embryo becomes a whole organism in vivo bioassay that can produce a phenotype upon treatment. Screens have been performed that are based simply on the morphology of the embryo. Other screens have scored complex phenotypes using whole mount in situ hybridization, fluorescent transgenic reporters, and even tracking of embryo movement. The availability of many well-characterized zebrafish mutants has also enabled the discovery of chemical suppressors of genetic phenotypes. Importantly, the application of chemical libraries that already contain FDA-approved drugs has allowed the rapid translation of hits from zebrafish chemical screens to clinical trials.